BRPI1012129A2 - enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos. - Google Patents

enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.

Info

Publication number: BRPI1012129A2
Authority: BR; Brazil
Prior art keywords: spiro; enantiomers; therapeutic agents; oxindole compounds; oxindole
Prior art date: 2009-06-29

Application number

BRPI1012129A

Other languages

English (en)

Inventor

Jean-Jacques Cadieux

Jlanmin Fu

Mikhail Chafeev

Original Assignee

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-29

Filing date

2010-06-28

Publication date

2016-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42416878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012129(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-28 Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc

2016-03-29 Publication of BRPI1012129A2 publication Critical patent/BRPI1012129A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Immunology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI1012129A 2009-06-29 2010-06-28 enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos. BRPI1012129A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22142409P	2009-06-29	2009-06-29
PCT/US2010/040187 WO2011002708A1 (en)	2009-06-29	2010-06-28	Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

Publications (1)

Publication Number	Publication Date
BRPI1012129A2 true BRPI1012129A2 (pt)	2016-03-29

Family

ID=42416878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1012129A BRPI1012129A2 (pt)	2009-06-29	2010-06-28	enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.

Country Status (34)

Country	Link
US (4)	US8450358B2 (pt)
EP (3)	EP2789617B1 (pt)
JP (3)	JP2012532107A (pt)
KR (1)	KR101751378B1 (pt)
CN (2)	CN104650106A (pt)
AR (1)	AR077252A1 (pt)
AU (1)	AU2010266549B2 (pt)
BR (1)	BRPI1012129A2 (pt)
CA (1)	CA2764878C (pt)
CL (1)	CL2011003335A1 (pt)
CO (1)	CO6470866A2 (pt)
CY (1)	CY1117776T1 (pt)
DK (1)	DK2448943T3 (pt)
EC (1)	ECSP11011512A (pt)
ES (2)	ES2578779T3 (pt)
HR (2)	HRP20110946A2 (pt)
HU (1)	HUE029658T2 (pt)
IL (3)	IL217285A (pt)
MA (1)	MA33552B1 (pt)
MX (2)	MX342298B (pt)
MY (1)	MY159099A (pt)
NZ (1)	NZ596903A (pt)
PE (2)	PE20120413A1 (pt)
PH (2)	PH12011502619A1 (pt)
PL (2)	PL2448943T3 (pt)
PT (1)	PT2448943T (pt)
RU (1)	RU2535667C2 (pt)
SG (1)	SG176307A1 (pt)
SI (1)	SI2448943T1 (pt)
SM (1)	SMT201600203B (pt)
TN (1)	TN2011000664A1 (pt)
TW (1)	TWI465452B (pt)
WO (1)	WO2011002708A1 (pt)
ZA (1)	ZA201108960B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9278088B2 (en)	2002-02-19	2016-03-08	Xenon Pharmaceuticals Inc.	Methods for identifying analgesic agents
MY145694A (en) *	2005-04-11	2012-03-30	Xenon Pharmaceuticals Inc	Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) *	2005-04-11	2007-11-07	Xenon Pharmaceuticals Inc	Compuestos espiro-oxindol y composiciones farmacéuticas
AU2007319580B2 (en)	2006-10-12	2012-11-29	Xenon Pharmaceuticals Inc.	Use of spiro-oxindole compounds as therapeutic agents
US20110294842A9 (en) *	2006-10-12	2011-12-01	Xenon Pharmaceuticals Inc.	Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2010045197A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Spiro-oxindole compounds and their use as therapeutic agents
MY155255A (en)	2008-10-17	2015-09-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their use as therapeutic agents
MX2011013816A (es)	2009-06-29	2012-04-11	Incyte Corp	Pirimidinonas como inhibidores de pi3k.
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ622072A (en)	2009-10-14	2015-10-30	Xenon Pharmaceuticals Inc	Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
US8759359B2 (en)	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
JP2013521232A (ja) *	2010-02-26	2013-06-10	ゼノン・ファーマシューティカルズ・インコーポレイテッド	局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
WO2011130342A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
WO2012049555A1 (en)	2010-10-13	2012-04-19	Lupin Limited	Spirocyclic compounds as voltage-gated sodium channel modulators
ES2764848T3 (es)	2010-12-20	2020-06-04	Incyte Holdings Corp	N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en)	2011-03-14	2015-08-18	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20230038593A (ko)	2011-09-02	2023-03-20	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
EP2638908A1 (en) *	2012-03-16	2013-09-18	Phytotox SpA	Paralytic Shellfish Poison
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2869547A1 (en) *	2012-04-12	2013-10-17	Xenon Pharmaceuticals Inc.	Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
GB201209015D0 (en) *	2012-05-22	2012-07-04	Convergence Pharmaceuticals	Novel compounds
KR20150119082A (ko) *	2013-02-13	2015-10-23	노파르티스 아게	국소 안구 진통제
AP2016009287A0 (en)	2013-12-13	2016-06-30	Vertex Pharma	Prodrugs of pyridone amides useful as modulators of sodium channels
WO2015120151A1 (en)	2014-02-05	2015-08-13	Teva Pharmaceuticals International Gmbh	Topical formulation of a spiro-oxindole compound for treating pain associated with osteoarthritis of a joint
MA39778A (fr)	2014-03-29	2017-02-08	Lupin Ltd	Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016109795A1 (en)	2014-12-31	2016-07-07	Concert Pharmaceuticals, Inc.	Deuterated funapide and difluorofunapide
AR103636A1 (es)	2015-02-05	2017-05-24	Teva Pharmaceuticals Int Gmbh	Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
PE20180129A1 (es)	2015-02-27	2018-01-18	Incyte Corp	Sales de inhibidor de pi3k y procesos de preparacion
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9840513B2 (en) *	2015-07-16	2017-12-12	Abbvie S.Á.R.L.	Substituted tricyclics and method of use
TW201722938A (zh)	2015-09-04	2017-07-01	魯賓有限公司	作為電位閘控鈉通道調節子之磺醯胺化合物
KR20180095598A (ko)	2015-12-18	2018-08-27	머크 샤프 앤드 돔 코포레이션	전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물
WO2017218920A1 (en)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Asymmetric synthesis of funapide
CA3026885A1 (en)	2016-06-16	2017-12-21	Xenon Pharmaceuticals Inc.	Solid state forms of spiro-oxindole compounds
WO2018163077A1 (en)	2017-03-08	2018-09-13	Lupin Limited	Indanyl compounds as voltage gated sodium channel modulators
EP3592747A1 (en)	2017-03-10	2020-01-15	Council of Scientific and Industrial Research	Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof
UA124857C2 (uk)	2017-05-16	2021-12-01	Вертекс Фармасьютикалз Інкорпорейтед	Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів
ES3008911T3 (en)	2017-07-11	2025-03-25	Vertex Pharma	Carboxamides as modulators of sodium channels
AU2018347349A1 (en)	2017-10-10	2020-04-23	Biogen Inc.	Process for preparing spiro derivatives
AU2019218387A1 (en)	2018-02-12	2020-08-27	Vertex Pharmaceuticals Incorporated	A method of treating pain
KR20210018328A (ko)	2018-06-01	2021-02-17	인사이트 코포레이션	Pi3k 관련 장애의 치료를 위한 투여 요법
EP3820866A4 (en)	2018-07-09	2022-04-06	Lieber Institute, Inc.	PYRIDINE CARBOXAMIDE COMPOUNDS TO INHIBIT NAV1.8
JP7623275B2 (ja)	2018-07-09	2025-01-28	リーバーインスティチュートインコーポレイテッド	ＮａＶ１．８を阻害するピリダジン化合物
WO2020054670A1 (ja)	2018-09-10	2020-03-19	科研製薬株式会社	新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬
WO2020146612A1 (en)	2019-01-10	2020-07-16	Vertex Pharmaceuticals Incorporated	Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en)	2019-01-10	2020-07-16	Vertex Pharmaceuticals Incorporated	Carboxamides as modulators of sodium channels
WO2020163372A1 (en)	2019-02-05	2020-08-13	Motive Drilling Technologies, Inc.	Downhole display
WO2020163242A1 (en)	2019-02-05	2020-08-13	Magnetic Variation Services, Llc	Geosteering methods and systems for improved drilling performance
WO2020176763A1 (en)	2019-02-27	2020-09-03	Vertex Pharmaceuticals Incorporated	Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en)	2019-04-25	2020-10-29	Vertex Pharmaceuticals Incorporated	Pyridone amide co-crystal compositions for the treatment of pain
UY38979A (es)	2019-12-06	2021-07-30	Vertex Pharma	Tetrahidrofuranos sustituidos como moduladores de canales de sodio
WO2022192427A1 (en)	2021-03-10	2022-09-15	Pacira Therapeutics, Inc.	Sustained release thermosetting gels comprising sodium channel blockers and the methods of making the same
AU2022285758A1 (en)	2021-06-04	2023-11-30	Vertex Pharmaceuticals Incorporated	Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3221939A1 (en)	2021-06-04	2022-12-08	Vertex Pharmaceuticals Incorporated	N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
KR20240031299A (ko)	2021-06-04	2024-03-07	버텍스 파마슈티칼스 인코포레이티드	(2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
EP4347031A1 (en)	2021-06-04	2024-04-10	Vertex Pharmaceuticals Incorporated	N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CA3221788A1 (en)	2021-06-04	2022-12-08	Vertex Pharmaceuticals Incorporated	Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347033A1 (en)	2021-06-04	2024-04-10	Vertex Pharmaceuticals Incorporated	Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
RU2763140C1 (ru) *	2021-06-29	2021-12-27	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	4-[2-(гидроксиметил)-фениламино]-6',6'-диметил-1'-(2-фторфенил)-3-(4-хлорбензоил)-6',7'-дигидро-5Н-спиро[фуран-2,3'-индол]-2',4',5(1'H,5'H)-трион в качестве средства, обладающего противомикробной активностью
AU2023255558A1 (en)	2022-04-22	2024-10-31	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en)	2022-04-22	2024-10-31	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
IL316422A (en)	2022-04-22	2024-12-01	Vertex Pharma	Heteroaryl compounds for pain treatment
PE20251179A1 (es)	2022-04-22	2025-04-23	Vertex Pharma	Compuestos de heteroarilo para el tratamiento del dolor
WO2024123815A1 (en)	2022-12-06	2024-06-13	Vertex Pharmaceuticals Incorporated	Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025005635A1 (en) *	2023-06-28	2025-01-02	Avelos Therapeutics Inc.	Substituted spiro compound derivatives and their pharmaceutical use
WO2025090465A1 (en)	2023-10-23	2025-05-01	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en)	2023-10-23	2025-05-01	Vertex Pharmaceuticals Incorporated	Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en)	2023-10-23	2025-05-01	Vertex Pharmaceuticals Incorporated	Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en)	2023-10-23	2025-05-01	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds for the treatment of pain
US20250186419A1 (en)	2023-12-07	2025-06-12	Vertex Pharmaceuticals Incorporated	Dosing regimens for treating pain

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3189617A (en)	1961-02-03	1965-06-15	Sterling Drug Inc	1-aryloxindoles and their preparation
DE1956237A1 (de)	1969-11-08	1971-05-13	Basf Ag	Spiro-pyrrolizidon-oxindole
DE2113343A1 (de)	1971-03-19	1972-09-21	Thiemann Chem Pharm Fab	Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en)	1971-04-23	1973-03-27	Mc Neil Labor Inc	2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
CH577461A5 (pt)	1975-08-13	1976-07-15	Robins Co Inc A H
US4670566A (en)	1979-07-12	1987-06-02	A. H. Robins Company, Incorporated	3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US4440785A (en)	1980-10-30	1984-04-03	A. H. Robins Company, Inc.	Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en)	1981-11-12	1984-03-20	The Upjohn Company	Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja)	1983-12-28	1985-07-29	Kyorin Pharmaceut Co Ltd	新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en)	1984-05-04	1986-02-11	Pfizer Inc.	N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) *	1984-07-23	1986-02-12	Ono Pharmaceut Co Ltd	プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en)	1984-09-19	1987-09-01	Pfizer Inc.	Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en)	1984-12-18	1988-01-26	Rorer Pharmaceutical Corporation	6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) *	1986-03-07	1995-11-16	Schering Ag	Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (en)	1986-07-10	1993-07-08	Howard Harry R Jr	Indolinone derivatives
HU206084B (en) *	1987-07-17	1992-08-28	Schering Ag	Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
US5182289A (en)	1988-06-14	1993-01-26	Schering Corporation	Heterobicyclic compounds having antiinflammatory activity
WO1991001306A1 (fr)	1989-07-25	1991-02-07	Taiho Pharmaceutical Company, Limited	Derive oxoindole
DE3932953A1 (de)	1989-10-03	1991-04-11	Boehringer Mannheim Gmbh	Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de)	1989-10-25	1991-05-02	Boehringer Mannheim Gmbh	Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5023265A (en)	1990-06-01	1991-06-11	Schering Corporation	Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en)	1990-07-17	2001-05-08	Univ Cleveland Hospitals	Phthalocynine photosensitizers for photodynamic therapy and methods for their use
JPH06502628A (ja)	1990-11-22	1994-03-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	除草作用をもつイソニコチン酸誘導体および関係するスピロ化合物
US5116854A (en)	1991-06-28	1992-05-26	Pfizer Inc.	Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
FR2708605A1 (fr)	1993-07-30	1995-02-10	Sanofi Sa	Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr)	1992-01-30	1995-06-30	Sanofi Elf	Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en)	1992-01-30	1997-11-11	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en)	1992-01-30	1998-12-15	Sanofi	1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en)	1992-01-30	1997-09-02	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5314685A (en)	1992-05-11	1994-05-24	Agouron Pharmaceuticals, Inc.	Anhydrous formulations for administering lipophilic agents
SK283413B6 (sk)	1992-08-06	2003-07-01	Warner-Lambert Company	2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
US5278162A (en)	1992-09-18	1994-01-11	The Du Pont Merck Pharmaceutical Company	3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en)	1992-10-07	1994-03-22	The Dupont Merck Pharmaceutical Co.	1-substituted oxindoles as cognition enhancers
US5776936A (en)	1992-11-13	1998-07-07	Pharmacia & Upjohn Company	Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de)	1992-12-16	1994-06-23	Basf Ag	Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en)	1993-01-22	1994-03-29	Pfizer Inc.	6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5994341A (en) *	1993-07-19	1999-11-30	Angiogenesis Technologies, Inc.	Anti-angiogenic Compositions and methods for the treatment of arthritis
FR2708606B1 (fr)	1993-07-30	1995-10-27	Sanofi Sa	Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en)	1993-11-26	1996-03-26	Pfizer Inc.	Substituted oxindoles
AT400950B (de)	1994-02-04	1996-04-25	Immodal Pharmaka Gmbh	Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
CN1047386C (zh)	1994-04-07	1999-12-15	西玛夫公司	新型褪黑激素拮抗物螺旋[吲哚吡咯烷丁]衍生物,其制备方法及其作为药物产品的用途
FR2722195B1 (fr)	1994-07-07	1996-08-23	Adir	Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en)	1994-07-07	1997-04-08	Adir Et Compagnie	1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
WO1996019477A1 (en)	1994-12-22	1996-06-27	Smithkline Beecham Plc	Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
FR2740136B1 (fr)	1995-10-24	1998-01-09	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
CA2235686C (en)	1995-10-24	2007-06-26	Sanofi	Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them
HUP9600855A3 (en)	1996-04-03	1998-04-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing tenidap
JPH1095766A (ja)	1996-09-19	1998-04-14	Sanwa Kagaku Kenkyusho Co Ltd	アセトアミド誘導体、及びその用途
FR2757157B1 (fr)	1996-12-13	1999-12-31	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE467418T1 (de)	1997-01-20	2010-05-15	Immodal Pharmaka Gmbh	Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
NO317155B1 (no) *	1997-02-04	2004-08-30	Ono Pharmaceutical Co	<omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ATE237587T1 (de) *	1997-02-10	2003-05-15	Ono Pharmaceutical Co	11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
AU741482B2 (en)	1997-05-07	2001-11-29	Allergan Pharmaceuticals International Limited	Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
ATE260254T1 (de) *	1997-12-25	2004-03-15	Ono Pharmaceutical Co	Omega-cycloalkyl-prostaglandin e2 derivate
JP4087938B2 (ja) *	1998-02-04	2008-05-21	高砂香料工業株式会社	ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
CZ302147B6 (cs)	1998-04-01	2010-11-18	Nortran Pharmaceuticals Inc.	Aminocyklohexyletherová sloucenina, použití této slouceniny pri výrobe léciva, farmaceutická kompozice tuto slouceninu obsahující a tato sloucenina a kompozice pro použití pri lécení
US20040038970A1 (en)	1998-06-12	2004-02-26	Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp.	Beta-carboline compounds
US6235780B1 (en) *	1998-07-21	2001-05-22	Ono Pharmaceutical Co., Ltd.	ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (en)	1998-07-27	2000-02-10	Abbott Laboratories	Substituted oxazolines as antiproliferative agents
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
US6355648B1 (en)	1999-05-04	2002-03-12	American Home Products Corporation	Thio-oxindole derivatives
US6407101B1 (en)	1999-05-04	2002-06-18	American Home Products Corporation	Cyanopyrroles
DE60042620D1 (de)	1999-05-21	2009-09-03	Bristol Myers Squibb Co	Pyrrolotriazine als Kinase Hemmer.
DE60039078D1 (de)	1999-07-21	2008-07-10	Boehringer Ingelheim Pharma	Kleine moleküle zur behandlung von endzündlichen erkrankungen
HUP0203548A3 (en)	1999-07-21	2003-04-28	Astrazeneca Ab	New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
AU1846501A (en)	1999-11-26	2001-06-04	Bionomics Limited	Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
FR2807038B1 (fr)	2000-04-03	2002-08-16	Sanofi Synthelabo	Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
EP1330426A4 (en)	2000-10-13	2005-09-14	Bristol Myers Squibb Co	SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE
DE60120748T2 (de)	2000-11-10	2007-05-16	Eli Lilly And Co., Indianapolis	3-substituierte oxindolderivate als beta-3-agonisten
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en)	2001-06-26	2003-04-24	Pfizer Inc.	Spiropiperidine compounds as ligands for ORL-1 receptor
ATE325119T1 (de)	2001-08-14	2006-06-15	Lilly Co Eli	3-substituierte oxindol-beta-3-agonisten
US7244744B2 (en)	2001-11-01	2007-07-17	Icagen, Inc.	Piperidines
WO2003037274A2 (en)	2001-11-01	2003-05-08	Icagen, Inc.	Pyrazole-amides and-sulfonamides
DE60204718T2 (de)	2001-11-20	2006-05-18	Eli Lilly And Co., Indianapolis	3-substituierte oxindol beta 3 agonisten
SE0104341D0 (sv)	2001-12-20	2001-12-20	Astrazeneca Ab	New use
JP2005519921A (ja)	2002-01-28	2005-07-07	ファイザー株式会社	Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003078394A1 (en)	2002-03-15	2003-09-25	Eli Lilly And Company	Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
US7595311B2 (en)	2002-05-24	2009-09-29	Exelixis, Inc.	Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en)	2002-06-14	2002-07-24	Syngenta Ltd	Chemical compounds
IL165395A0 (en)	2002-06-25	2006-01-15	Wyeth Corp	Use of thio-oxubdile derivatives in treatment of hormone-related conditions
JP2005535625A (ja)	2002-06-25	2005-11-24	ワイス	皮膚障害の治療におけるチオオキシインドール誘導体の使用
US7256218B2 (en)	2002-11-22	2007-08-14	Jacobus Pharmaceutical Company, Inc.	Biguanide and dihydrotriazine derivatives
KR20120102571A (ko)	2003-02-24	2012-09-18	미쓰비시 타나베 파마 코퍼레이션	테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도
AU2004237961A1 (en)	2003-05-16	2004-11-25	Pfizer Products Inc.	Treatment of bipolar disorders and associated symptoms
CA2625837A1 (en)	2003-05-16	2004-11-25	Pfizer Products Inc.	Method for enhancing cognition using ziprasidone
CA2525868A1 (en)	2003-05-16	2004-11-25	Pfizer Products Inc.	Anxiety treatments with ziprasidone
EP1633360A1 (en)	2003-05-16	2006-03-15	Pfizer Products Incorporated	Treatment of psychotic and depressive disorders
KR20060037409A (ko)	2003-07-30	2006-05-03	제논 파마슈티칼스 인크.	피페라진 유도체 및 그의 치료제로서의 용도
DE10337184A1 (de)	2003-08-13	2005-03-10	Gruenenthal Gmbh	Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (en)	2003-08-19	2005-02-24	Pfizer Japan, Inc.	Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
WO2005035498A1 (ja)	2003-10-08	2005-04-21	Dainippon Sumitomo Pharma Co., Ltd.	含窒素二環性化合物の摂食調節剤としての用途
EP1557166A1 (en)	2004-01-21	2005-07-27	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
US7507760B2 (en)	2004-01-22	2009-03-24	Neuromed Pharmaceuticals Ltd.	N-type calcium channel blockers
GB0406867D0 (en)	2004-03-26	2004-04-28	F2G Ltd	Antifungal agents
EP1732564A1 (en)	2004-03-29	2006-12-20	Merck & Co., Inc.	Biaryl substituted pyrazinones as sodium channel blockers
CA2563164A1 (en)	2004-03-29	2005-10-06	Pfizer Inc.	Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
GT200500063A (es)	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
WO2005099689A1 (en)	2004-04-01	2005-10-27	Case Western Reserve University	Topical delivery of phthalocyanines
EA013209B1 (ru)	2004-04-08	2010-04-30	Топотаргет А/С	Производные дифенилоксиндол-2-она и их применение для лечения рака
MXPA06012403A (es)	2004-04-27	2007-01-17	Wyeth Corp	Purificacion de moduladores de receptor progesterona.
JP2007536283A (ja)	2004-05-05	2007-12-13	ユニバイオスクリーンエス．アー．	ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
MXPA06011658A (es)	2004-05-14	2006-12-14	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
CN101001850A (zh)	2004-06-24	2007-07-18	因塞特公司	酰胺基化合物及其作为药物的应用
GT200500186A (es)	2004-07-07	2006-03-02		Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es)	2004-08-09	2006-04-10		Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es)	2004-08-09	2006-04-10		Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja)	2004-11-01	2011-04-27	キヤノン株式会社	画像処理装置及び画像処理方法
CN101103016A (zh)	2004-11-18	2008-01-09	因塞特公司	11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
DE102005007694A1 (de)	2005-02-18	2006-09-21	Henkel Kgaa	Mittel zum Färben von keratinhaltigen Fasern
JP5248866B2 (ja)	2005-02-22	2013-07-31	ザリージェンツオブザユニバーシティオブミシガン	Ｍｄｍ２の小分子阻害剤およびその使用
MY145694A (en)	2005-04-11	2012-03-30	Xenon Pharmaceuticals Inc	Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) *	2005-04-11	2007-11-07	Xenon Pharmaceuticals Inc	Compuestos espiro-oxindol y composiciones farmacéuticas
AR056317A1 (es)	2005-04-20	2007-10-03	Xenon Pharmaceuticals Inc	Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es)	2005-04-20	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos heterociclicos y sus usos como agentes terapeuticos
US7595338B2 (en)	2005-04-29	2009-09-29	Wyeth	Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
EP1888581A2 (en)	2005-05-16	2008-02-20	Gilead Sciences, Inc.	Hiv-integrase inhibitor compounds
AU2006286601B2 (en)	2005-09-01	2012-07-05	F. Hoffmann-La Roche Ag	Diaminopyrimidines as P2X3 and P2X2/3 modulators
JP2009543762A (ja)	2006-06-09	2009-12-10	メルクエンドカムパニーインコーポレーテッド	ナトリウムチャネル遮断薬としてのベンゾアゼピノン
WO2008046087A2 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Spiro compounds and their uses as therapeutic agents
WO2008046084A2 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046065A1 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Spiroheterocyclic compounds and their uses as therapeutic agents
AU2007319580B2 (en)	2006-10-12	2012-11-29	Xenon Pharmaceuticals Inc.	Use of spiro-oxindole compounds as therapeutic agents
WO2008046083A2 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Use of oxindole compounds as therapeutic agents
WO2008046082A2 (en)	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Use of heterocyclic compounds as therapeutic agents
US20110294842A9 (en)	2006-10-12	2011-12-01	Xenon Pharmaceuticals Inc.	Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046046A1 (en) *	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
GB0704846D0 (en)	2007-03-13	2007-04-18	Futura Medical Dev Ltd	Topical pharmaceutical formulation
WO2008117050A1 (en)	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
KR101528378B1 (ko) *	2007-05-29	2015-06-11	인트렉손 코포레이션	엑디손 수용체 복합체를 통한 외인성 유전자 발현 조절용 카이랄 디아실히드라진 리간드
WO2010045197A1 (en)	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Spiro-oxindole compounds and their use as therapeutic agents
MY155255A (en)	2008-10-17	2015-09-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (en)	2008-11-05	2010-05-14	Xenon Pharmaceuticals, Inc.	Spiro-condensed indole derivatives as sodium channel inhibitors
US20110269788A1 (en) *	2008-12-29	2011-11-03	Xenon Pharmaceuticals Inc.	Spiro-oxindole-derivatives as sodium channel blockers
WO2010132352A2 (en)	2009-05-11	2010-11-18	Xenon Pharmaceuticals Inc.	Spiro compounds and their use as therapeutic agents
AR077252A1 (es) *	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ622072A (en) *	2009-10-14	2015-10-30	Xenon Pharmaceuticals Inc	Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
JP2013521232A (ja)	2010-02-26	2013-06-10	ゼノン・ファーマシューティカルズ・インコーポレイテッド	局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
CA2869547A1 (en)	2012-04-12	2013-10-17	Xenon Pharmaceuticals Inc.	Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

2010
- 2010-06-25 AR ARP100102282A patent/AR077252A1/es unknown
- 2010-06-28 PL PL10731662.2T patent/PL2448943T3/pl unknown
- 2010-06-28 MY MYPI2011006363A patent/MY159099A/en unknown
- 2010-06-28 CA CA2764878A patent/CA2764878C/en active Active
- 2010-06-28 US US12/825,168 patent/US8450358B2/en active Active
- 2010-06-28 HR HR20110946A patent/HRP20110946A2/hr not_active Application Discontinuation
- 2010-06-28 RU RU2012102896/04A patent/RU2535667C2/ru not_active IP Right Cessation
- 2010-06-28 AU AU2010266549A patent/AU2010266549B2/en active Active
- 2010-06-28 EP EP14000690.9A patent/EP2789617B1/en active Active
- 2010-06-28 JP JP2012517823A patent/JP2012532107A/ja not_active Withdrawn
- 2010-06-28 EP EP16001748.9A patent/EP3156407A1/en not_active Withdrawn
- 2010-06-28 ES ES10731662.2T patent/ES2578779T3/es active Active
- 2010-06-28 CN CN201510007582.0A patent/CN104650106A/zh active Pending
- 2010-06-28 MX MX2013008427A patent/MX342298B/es unknown
- 2010-06-28 MX MX2012000028A patent/MX2012000028A/es active IP Right Grant
- 2010-06-28 PL PL14000690T patent/PL2789617T3/pl unknown
- 2010-06-28 SG SG2011090081A patent/SG176307A1/en unknown
- 2010-06-28 BR BRPI1012129A patent/BRPI1012129A2/pt not_active IP Right Cessation
- 2010-06-28 HR HRP20160732TT patent/HRP20160732T1/hr unknown
- 2010-06-28 ES ES14000690.9T patent/ES2600160T3/es active Active
- 2010-06-28 HU HUE10731662A patent/HUE029658T2/en unknown
- 2010-06-28 DK DK10731662.2T patent/DK2448943T3/en active
- 2010-06-28 PT PT107316622T patent/PT2448943T/pt unknown
- 2010-06-28 PE PE2011002098A patent/PE20120413A1/es not_active Application Discontinuation
- 2010-06-28 CN CN201080029572.2A patent/CN102471347B/zh active Active
- 2010-06-28 NZ NZ596903A patent/NZ596903A/en unknown
- 2010-06-28 EP EP10731662.2A patent/EP2448943B1/en active Active
- 2010-06-28 WO PCT/US2010/040187 patent/WO2011002708A1/en active Application Filing
- 2010-06-28 SI SI201031198A patent/SI2448943T1/sl unknown
- 2010-06-28 PH PH1/2011/502619A patent/PH12011502619A1/en unknown
- 2010-06-28 KR KR1020117031238A patent/KR101751378B1/ko not_active Expired - Fee Related
- 2010-06-28 PE PE2015002585A patent/PE20160216A1/es not_active Application Discontinuation
- 2010-06-29 TW TW099121292A patent/TWI465452B/zh not_active IP Right Cessation
2011
- 2011-12-06 ZA ZA2011/08960A patent/ZA201108960B/en unknown
- 2011-12-06 CO CO11168005A patent/CO6470866A2/es not_active Application Discontinuation
- 2011-12-09 EC EC2011011512A patent/ECSP11011512A/es unknown
- 2011-12-16 MA MA34459A patent/MA33552B1/fr unknown
- 2011-12-23 TN TNP2011000664A patent/TN2011000664A1/en unknown
- 2011-12-28 CL CL2011003335A patent/CL2011003335A1/es unknown
- 2011-12-29 IL IL217285A patent/IL217285A/en not_active IP Right Cessation
2012
- 2012-09-14 US US13/619,915 patent/US8883840B2/en not_active Expired - Fee Related
2014
- 2014-10-09 US US14/510,634 patent/US9480677B2/en not_active Expired - Fee Related
- 2014-11-20 JP JP2014235262A patent/JP2015038153A/ja not_active Withdrawn
2015
- 2015-10-07 PH PH12015502323A patent/PH12015502323A1/en unknown
- 2015-10-08 IL IL241985A patent/IL241985A/en not_active IP Right Cessation
2016
- 2016-06-28 CY CY20161100581T patent/CY1117776T1/el unknown
- 2016-06-29 SM SM201600203T patent/SMT201600203B/it unknown
- 2016-09-28 US US15/278,759 patent/US20170073351A1/en not_active Abandoned
- 2016-10-07 JP JP2016198877A patent/JP2017002085A/ja not_active Withdrawn
2017
- 2017-01-26 IL IL250314A patent/IL250314A0/en unknown

Also Published As

Publication number	Publication date
CN102471347A (zh)	2012-05-23
JP2017002085A (ja)	2017-01-05
CA2764878A1 (en)	2011-01-06
TN2011000664A1 (en)	2013-05-24
TWI465452B (zh)	2014-12-21
US8883840B2 (en)	2014-11-11
IL241985A0 (en)	2015-11-30
DK2448943T3 (en)	2016-07-04
HUE029658T2 (en)	2017-03-28
AU2010266549A1 (en)	2012-01-19
ES2578779T3 (es)	2016-08-01
EP2789617A1 (en)	2014-10-15
EP2789617B1 (en)	2016-08-17
JP2015038153A (ja)	2015-02-26
PE20160216A1 (es)	2016-05-11
MA33552B1 (fr)	2012-09-01
PT2448943T (pt)	2016-07-12
PE20120413A1 (es)	2012-05-13
US8450358B2 (en)	2013-05-28
US20130072537A1 (en)	2013-03-21
RU2012102896A (ru)	2013-08-10
AR077252A1 (es)	2011-08-10
CY1117776T1 (el)	2017-05-17
MX2012000028A (es)	2012-01-30
ES2600160T3 (es)	2017-02-07
HK1168854A1 (zh)	2013-01-11
IL217285A0 (en)	2012-02-29
KR20120101980A (ko)	2012-09-17
CN102471347B (zh)	2015-07-29
ZA201108960B (en)	2013-03-27
NZ596903A (en)	2014-04-30
WO2011002708A1 (en)	2011-01-06
CO6470866A2 (es)	2012-06-29
HRP20110946A2 (hr)	2012-01-31
CA2764878C (en)	2018-08-07
MX342298B (es)	2016-09-23
PL2789617T3 (pl)	2017-02-28
ECSP11011512A (es)	2012-01-31
RU2535667C2 (ru)	2014-12-20
HK1203192A1 (en)	2015-10-23
MY159099A (en)	2016-12-15
EP2448943B1 (en)	2016-03-30
EP3156407A1 (en)	2017-04-19
TW201105677A (en)	2011-02-16
PH12011502619A1 (en)	2021-06-23
PH12015502323A1 (en)	2019-08-19
CL2011003335A1 (es)	2012-05-25
SMT201600203B (it)	2016-08-31
PL2448943T3 (pl)	2016-09-30
US20170073351A1 (en)	2017-03-16
JP2012532107A (ja)	2012-12-13
EP2448943A1 (en)	2012-05-09
HRP20160732T1 (hr)	2016-07-15
IL241985A (en)	2017-02-28
US20100331386A1 (en)	2010-12-30
IL250314A0 (en)	2017-03-30
AU2010266549B2 (en)	2015-06-25
SG176307A1 (en)	2012-01-30
US20150025121A1 (en)	2015-01-22
CN104650106A (zh)	2015-05-27
KR101751378B1 (ko)	2017-06-28
SI2448943T1 (sl)	2016-07-29
US9480677B2 (en)	2016-11-01
IL217285A (en)	2016-09-29

Publication	Publication Date	Title
BRPI1012129A2 (pt)	2016-03-29	enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
CL2014003228A1 (es)	2015-02-27	Sintesis e intermediarios de compuestos heterocíclicos biologicamente activas.
BRPI0907918A2 (pt)	2015-07-28	Ácidos sulfoperoxicarxílicos, sua preparação e métodos de utilizção como agentes alvejantes e antimicrobianos
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
BRPI1011587A2 (pt)	2016-03-22	compostos e composições terapèuticas
BR112013002845A2 (pt)	2016-06-07	combinação de susbtâncias ativas
EP2296593A4 (en)	2015-01-14	MEDICAL HEAD COVER
BR112013013311A2 (pt)	2017-09-19	agente terapêutico de indução de citotoxicidade
EP2327448A4 (en)	2012-05-30	defibrillation catheter
EP2513299A4 (en)	2013-12-11	ADIPEOUS FABRIC DECELLULARIZED
BRPI0917017A2 (pt)	2016-02-16	inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
EP2641343A4 (en)	2014-04-16	CONFIGURATION OF A BUILDING
ME03508B (me)	2020-04-20	Kombinovana terapija za liječenje dijabetesa
ATE526024T1 (de)	2011-10-15	Fluvoxamin vermeidende pirfenidontheraphy
HUE054196T2 (hu)	2021-08-30	Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére
DK2593060T3 (da)	2013-11-18	Engangsble
DK2627345T3 (da)	2014-09-01	Formuleringer til behandling af sygdomme i de øvre luftveje
EP2606916A4 (en)	2014-01-08	BIOLOGICAL IMPLANT
BRPI1006504A2 (pt)	2018-06-05	fralda descartavel
SMT201600041B (it)	2016-02-25	Agenti terapeutici 713
BRPI1007543A2 (pt)	2016-02-16	tratamento de psoríase
PT2774612T (pt)	2017-11-17	Formulações de 4-metilpirazol
BRPI1013903A2 (pt)	2016-07-19	tratamentos terapêuticos utilizando centaquina
BR112012003026A2 (pt)	2016-08-16	formulações e métodos de emprego de desinfetante anidro.
FR2943077B1 (fr)	2016-12-30	Plaque de passage.

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-04-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-24	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-08-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2520 DE 25-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.